D3 Bio Launches with $200 Million to Advance Precision Medicine in Oncology and Immunology Space
On November 17th, global biotech D3 Bio launched with a $200 million Series A financing by Boyu Capital, Matrix Partners China, Wuxi AppTech, Temasek, and Sequoia. The funding will support …
Read More